The present study aimed to investigate the effect of Proknee Collagen II™ on joint health and quality of life. A 12-week, randomized, double-blind, placebo controlled, parallel study was conducted in Adults aged 40-65 years with joint pain diagnosed as Grade II knee OA in a 1:1:1 ratio. At day 84, Proknee Collagen II™ demonstrated a statistically significant result in the joint health when compared to placebo. Proknee Collagen IITM was able to significantly improve the joint health and quality of life of participants, and was well-tolerated.

Vitex negundo and Zingiber officinale containing proprietary formula, E-PR-01 was studied in a randomized, double-blind, placebo-controlled cross-over to investigate its efficacy and safety on knee joint discomfort due to pain. Forty adults aged 20– 60 years with self-reported pain score were randomized in a 1:1 ratio. The results were statistically significant.

Knee osteoarthritis (OA) is the most common form of clinical arthritis in middle-aged and older individuals. Undenatured or native type II (TII) collagen derived from the chicken sternum has a good therapeutic effect on relieving severe pain of OA. Hence, the present study aimed to investigate the efficacy and safety of TII collagen (Native CT-II®) in individuals with knee OA.

Vedic conducted a 12-week randomised, double-blind, placebo-controlled, parallel-group study on 101
participants aged 40–65 years with knee OA. The participants were randomised to receive either TII collagen, glucosamine hydrochloride+chondroitin sulfate (G+C) or a placebo. The primary outcome was an improvement in the joint health of the participants assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) compared to G+C and placebo.

A Canadian group approached Vedic in 2004 to conduct a study in India that would be acceptable to US regulators. This was the first study for us that had to meet US standards because so far we had been serving only the Indian market. We took up the challenge to design a study to meet FTC and FDA standards for dietary supplement clinical research. This study was to determine the joint protection potential of a natural mineral supplement, Sierrasil with and without cat’s claw extract. Possibly for the first time, the gold standard of human research – Good Clinical Practice (ICH/FDA GCP) was applied to a food supplement study. Our client received an NPN based on this publication and went on to use these label claims in Canada as well as in the US.

The study was conducted to assess the effect of IP in subjects with osteoarthritis with mild to moderate pain. The effect of the treatment on rescue medication consumption which is directly proportional to the degree of pain was also be captured via this study. the efficacy parameters such as effect on various joint health parameters (pain, stiffness and physical activity) were studied by using the WOMAC scale. The individuals with knee OA suffer from an increased impact on their activities of daily living, leading also to an important decrease in their quality of life. Thus, an important outcome to be evaluated in this study is the quality of life of these individuals which was also assessed. One of the aims of this study is therefore to investigate the levels of different dimensions of fatigue in knee OA and to assess changes in fatigue after the treatment targeting pain reduction and physical functioning.